A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine.

Trial Profile

A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine.

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Jan 2013

At a glance

  • Drugs Efavirenz; Emtricitabine; Lamivudine; Lopinavir/ritonavir; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 23 Feb 2012 Actual patient number (346) added as reported by ClinicalTrials.gov.
    • 13 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Oct 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top